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Promoter CpG methylation of tumour suppressor genes (TSGs) is an epigenetic biomarker for TSG identification and molecular
diagnosis. We screened genome wide for novel methylated genes through methylation subtraction of a genetic demethylation model
of colon cancer (double knockout of DNMT1 and DNMT3B in HCT116) and identified DLEC1 (Deleted in lung and oesophageal
cancer 1), a major 3p22.3 TSG, as one of the methylated targets. We further found that DLEC1 was downregulated or silenced in
most colorectal and gastric cell lines due to promoter methylation, whereas broadly expressed in normal tissues including colon and
stomach, and unmethylated in expressing cell lines and immortalised normal colon epithelial cells. DLEC1 expression was reactivated
through pharmacologic or genetic demethylation, indicating a DNMT1/DNMT3B-mediated methylation silencing. Aberrant
methylation was further detected in primary colorectal (10 out of 34, 29%) and gastric tumours (30 out of 89, 34%), but seldom in
paired normal colon (0 out of 17) and gastric (1 out of 20, 5%) samples. No correlation between DLEC1 methylation and clinical
parameters of gastric cancers was found. Ectopic expression of DLEC1 in silenced HCT116 and MKN45 cells strongly inhibited their
clonogenicity. Thus, DLEC1 is a functional tumour suppressor, being frequently silenced by epigenetic mechanism in gastrointestinal
tumours.
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Tumorigenesis is a multistep process, with colorectal cancer (CRC)
as the prototype model for multi-step genetic pathogenesis
(Kinzler and Vogelstein, 1996). In this model, the key molecular
event is the inactivation of multiple tumour suppressor genes
(TSGs) due to genetic alterations. Also, it is now well established
that alternative epigenetic silencing, such as methylation of
promoter CpG islands (CGIs), leads to the inactivation of TSGs
in virtually all tumour types and plays significant roles in tumour
initiation and progression (Jones and Baylin, 2002). In CRC,
epigenetic silencing of multiple TSGs has been reported frequently,
including MLH1, p16
INK4A, MGMT, VHL, APC, RASSF1A, HIC1,
CHFR, ADAMTS18 and PCDH10 in various percentages of CRC
tumours (Herman et al, 1998; Esteller et al, 2001; Kim et al, 2005;
Ying et al, 2006; Jin et al, 2007 ). A growing list of TSGs with CGI
methylation-mediated silencing has also been reported in gastric
cancer (Leung et al, 2001). It is important to identify more new
TSGs that are silenced by tumour-specific methylation in CRC and
gastric cancers, which could serve as valuable biomarkers for
molecular diagnosis and also provide clues to the molecular
pathogenesis of these tumours.
In this study, we conducted a genome-wide search for genes
with promoter methylation in CRC, by utilising CpG methylation-
specific subtraction, in a CRC model of HCT116 cells deficient in
DNMT1 and DNMT3B (double knockout (DKO) cells). DNMT1
and DNMT3B are the two major DNA methyltransferases
responsible for the maintenance and de novo CpG methylation,
and the disruption of these two genes results in more than 95%
loss of overall genomic methylation and CGI demethylation (Rhee
et al, 2002). Virtually all known TSGs with methylation-mediated
silencing in HCT116 became demethylated and reactivated in
HCT116DKO, making it a good epigenetic model to identify novel
candidate TSGs silenced in tumours (Rhee et al, 2002; Paz et al,
2003; Ying et al, 2005). Among the methylated target genes we
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sidentified, one is DLEC1 (Deleted in lung and oesophageal cancer
1), located at 3p22.3 – a common tumour suppressor locus with
frequent genetic abnormalities in multiple cancers (Imreh et al,
2003). The expression of DLEC1 and its regulation in digestive
tumours have yet to be evaluated. We found that DLEC1
underwent promoter methylation-associated silencing in most
CRC and gastric tumour cell lines and primary tumours, in a
tumour-specific manner. Reintroduction of DLEC1 into silenced
tumour cells significantly suppressed tumour cell clonogenicity.
MATERIALS AND METHODS
Cell lines and primary tumours
Seven CRC (HCT116, HT29, LoVo, SW480, DLD1, LS180 and
SW620) and 17 gastric cancer (Kato III, YCC1, YCC2, YCC3, YCC6,
YCC7, YCC9, YCC10, YCC11, YCC16, SNU719, AGS, MKN28,
NCI87, SNU1, SNU16 and MKN45) cell lines were used. Cell lines
were routinely maintained in RPMI-1640 medium with 10%
FBS. HCT116 cell line with genetic knockout of DNA methyl-
transferase genes (DNMTs): HCT116 DNMT1 /  (DNMT1KO),
HCT116 DNMT3B /  (DNMT3BKO) and HCT116 DNMT1 / 
DNMT3B /  (DKO) (gift from Dr Bert Vogelstein, Johns
Hopkins) were grown with either 0.4mgml
 1 genecitin or
0.05mgml
 1 hygromycin or both (Rhee et al, 2002). DNA and
total RNA were extracted from cell lines using TRI REAGENT
(Molecular Research Center, Cincinnati, OH, USA). Genomic DNA
of another five CRC cell lines (HCT15, RKO, SW48, Caco-2 and
Colo205) and one immortalised normal colon epithelial cell line
CCD-841 was also used. Genomic DNA samples from primary
tumour tissues of 34 CRC and 89 gastric cancer patients were also
used, with DNA samples of matched surgical marginal normal
tissue samples from 17 CRC and 20 gastric cancer patients also
available. Clinical information was available for all gastric cancer
patients, including gender, differentiation, histological type
according to Laure ´n and tumour, node and metastasis (TNM)
stage. However, no survival data were available.
Pharmacologic demethylation
Cell lines with silenced DLEC1 were treated with 5mM of 5-aza-
20-deoxycytidine (Aza) (Sigma, St Louis, MO, USA) for 3 days as
described earlier (Ying et al, 2005). After the treatment, cells were
pelleted, with DNA and total RNA extracted.
Modified methylation-sensitive representational difference
analysis
To identify novel methylated TSGs, we employed a strategy of
modified methylation-sensitive representational difference analy-
sis (MS-RDA), using uracil-DNA glycosylase-based digestion
during MS-RDA (Sugai et al,1 9 9 8 ;K a n e d aet al, 2003), for DNA
samples of the wild-type and DNA methyltransferases (DNMT1
and -3B) DKO of HCT116 (Rhee et al, 2002). The method was
based on the principle that restriction enzymes (HpaII, SacII and
NarI) have different sensitivities towards sequences containing
5-methyl cytosine (CCGG, CCGCGG and GGCGCC). We further
selected candidate genes with typical promoter CGI and also
located at important chromosome loci commonly deleted in
tumours and possibly harbouring putative TSGs for more detailed
studies, such as DLEC1.
Semi-quantitative reverse transcription PCR
Reverse transcription PCR (RT–PCR) was performed as described
earlier (Tao et al, 2002; Ying et al, 2006), using GAPDH as a
control. The primers for DLEC1 are listed in Table 1. The PCR
programme utilised an initial denaturation at 951C for 10min,
followed by 33 cycles of reaction (941C for 30s, 551C for 30s and
721C for 30s), with a final extension at 721C for 10min.
Bisulphite treatment and promoter methylation analysis
Bisulphite modification of DNA was carried out as described
earlier using 2.4 M sodium metabisulphite (Tao et al, 2002).
Methylation-specific PCR (MSP) and bisulphite genomic sequen-
cing (BGS) were conducted according to our earlier reports (Tao
et al, 1999; Ying et al, 2006). Methylation-specific PCR primers are
listed in Table 1. Methylation-specific PCR was conducted at 951C
for 10min, followed by 40 cycles of reaction (941C, 30s; 581C for
M, 551C for U, 30s; 721C, 30s), ended by 721C for 5min.
Methylation-specific PCR primers were tested earlier for not
amplifying any non-bisulphite-treated genomic DNA and thus
specific. The MSP products of selected samples have been
confirmed by direct sequencing. The top strand-specific BGS
primers for bisulphite-converted single-stranded DNA of the
DLEC1 promoter are listed in Table 1. Amplified products were
cloned into the pCR4-Topo vector (Invitrogen, Carlsbad, CA,
USA), with six to eight colonies randomly chosen and sequenced.
Cloning of the human DLEC1 full-length open reading
frame
Four pairs of primers were used to generate four DLEC1 fragments
based on the published DLEC1 sequence (GenBank accession
number AB020522): I, II, III and IV, which contain restriction
enzyme sites of MfeI, NdeI and ApaLI, respectively. The sequences
of primers for these fragments are listed in Table 1. Reverse
transcription was carried out using normal human testis RNA as a
template (BD Biosciences, Palo Alto, CA, USA). Reverse transcrip-
tion PCR products were cloned into pCR II-TOPO vector
(Invitrogen) with the sequences and orientations confirmed from
both ends. The four fragments were then ligated to form the full-
length DLEC1 cDNA, which was then cloned into the pcDNA3.1
vector, using the restriction sites BamHI and MfeI (vector and
fragment I), MfeI and NdeI (fragment II), NdeI and ApaLI
(fragment III), and ApaL I and Xho I (fragment IV and vector),
to generate the recombinant vector pcDNA3.1-DLEC1.
Colony formation assay
Cells (1.5 10
5 per well). were plated in a 12-well plate and
transfected with either expression plasmid or the empty vector
(0.8mg each), using FuGENE 6 (Roche Diagnostics, Mannheim,
Germany). Forty-eight hours post-transfection, cells were collected
and plated in a six-well plate, and selected for 2 weeks with G418
(0.4mgml
 1). Surviving colonies (X50 cells per colony) were
counted after staining with Gentian Violet. Total RNA from the
transfected cells was extracted, treated with TURBO DNase
(Ambion, Austin, TX, USA) and analysed by RT–PCR to confirm
the ectopic expression of DLEC1. All the experiments were
performed in triplicate wells for three times.
Statistical analysis
Chi square test was used to analyse possible correlation between
clinical parameters and DLEC1 methylation status of tumour and
non-tumour samples. For colony formation assay, experimental
differences were tested for statistical significance using t-test. All
analyses were performed using SAS for windows, version 9
software (SAS Institute Inc., Cary, NC, USA). A P-value of o0.05
was considered significant.
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Epigenetic identification of DLEC1 as a methylated gene in
CRC
Using a modified MS-RDA to screen genome wide for methylated
sequences in HCT116 and its demethylated DKO cells, we
identified 22 hypermethylated DNA fragments/genes (Ying and
Tao, manuscript in preparation). Among these identified
sequences, one of particular interest is DLEC1, a candidate TSG
previously identified in lung cancer (Daigo et al, 1999). Although
no methylation was detected in this first report, the region
spanning the putative promoter and exon 1 of DLEC1 is a typical
CGI (Gardiner-Garden and Frommer, 1987) (Figure 1A) that is
susceptible to epigenetic silencing. We designed MSP and BGS
primers to analyse its methylation status. Methylation-specific
PCR analyses showed that DLEC1 was completely methylated in
HCT116 and became completely demethylated in DKO cells, but
only marginally demethylated in DNMT1KO and not demethylated
in DNMT3BKO cells. Correlated with its methylation status,
DLEC1 was silenced in HCT116, and only reactivated in DKO
cells, but not in DNMT1KO or DNMT3BKO cells (Figure 1B).
Detailed BGS analysis, revealing the methylation status of
individual CpG site of the DLEC1 promoter, showed that only
few scattered CpG sites remained methylated in DKO cells whereas
HCT116 was almost completely methylated (Figure 1C). These
results thus demonstrate a close relationship between the silencing
of DLEC1 and its promoter methylation in HCT116 and DKO cells.
Frequent methylation-associated silencing of DLEC1 in
CRC and gastric cell lines
To further examine the correlation of DLEC1 methylation and
silencing, we investigated additional human tissues and gastro-
intestinal cell lines. DLEC1 was found to be readily expressed in all
22 normal adult and 9 foetal tissues including colon, rectum and
stomach, with the highest level in testis and weak expression in
skeletal muscle and pancreas (Figure 2A), in agreement with the
earlier study that this gene is expressed in all tissues examined and
abundantly in testis (Daigo et al, 1999). In contrast, DLEC1 was
silenced or downregulated in six of seven CRC and 15 of 17 gastric
cancer cell lines (Figure 2B). By MSP, DLEC1 methylation was
Table 1 List of primers used in this study
PCR Primer Sequence Location Product size PCR cycles
Annealing
temperature (1C)
RT–PCR DLEC1A ttcctccctcgcctactc Exon 1 309bp 33 55
DLEC1B aaactcatccagccgctg Exon 2
cDNA cloning Fragment I gccgccaccatggagaccagggc Exon 1 B1.1kb 35 53
gtgaaaaacccaattggtgg Exon 6
Fragment II agtgtttctagctaagccac Exon 6 B1.2kb 35 53
gagggcatatggctctaag Exon 14
Fragment III cttagagccatatgccctc Exon 14 B1.4kb 35 53
gccatgtgcactgggatg Exon 25
Fragment IV catcccagtgcacatggc Exon 25 B1.6Kb 35 53
gctcgagcggagcctcaggg Exon 36
MSP DLEC1m1 gtttcgtagttcggtttcgtc Exon 1 107bp 40 58
DLEC1m2 cgaaatatcttaaatacgcaacg Exon 1
DLEC1u1 tagttttgtagtttggttttgtt Exon 1 110bp 40 55
DLEC1u2 acaaaatatcttaaatacacaaca Exon 1
BGS DLEC1BGS1 cgaagatataaatgtttataatgatt Promoter 597bp 40 55
DLEC1BGS4 caactacaaccccaaatcctaa Intron 1
BGS¼bisulphite genomic sequencing; MSP¼methylation-specific PCR.
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Figure 1 Identification of DLEC1 as a methylated gene in CRC (HCT116) cells. (A) Schematic illustration of the DLEC1 promoter and its CGI. Locations
of the exon 1 (indicated with a long rectangle) and CpG sites (short vertical lines) in the CGI are shown. The transcription start site is indicated by a curved
arrow. (B) Genetic demethylation reactivated DLEC1 expression in DKO cells. U: unmethylated; M: methylated. (C) Detailed BGS analysis confirmed the
MSP results. Methylation status of each individual promoter allele was shown as a row of CpG sites sequenced from each bacterium colony. Filled circle,
methylated; open circle, unmethylated.
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gastric cancer cell lines, with complete methylation detected in
most cell lines, whereas no methylation was seen in the normal
colon epithelial cell line CCD-841 (Figure 2B). Further BGS
methylation analysis for one CRC, two gastric cell lines and
CCD-841 confirmed the MSP results, with a high density of
methylated CpG sites detected in all tumour cell lines, but not in
CCD-841 (Figure 2C). Thus, the results revealed a strong
correlation between DLEC1 transcriptional silencing and its
promoter methylation in virtually all CRC and gastric cancer cell
lines examined, except for one CRC cell line LS180, which has both
methylated and unmethylated promoter alleles but DLEC1
expression is totally silenced, indicating that other mechanisms
such as histone modification also could not be excluded.
Restoration of DLEC1 expression by pharmacologic
demethylation
To determine whether methylation directly mediates the silencing
of DLEC1, two CRC (HCT116 – methylated, SW480 – unmethy-
lated) and two methylated gastric (YCC10 and SNU719) cancer cell
lines were treated with Aza, a DNA methyltransferase inhibitor.
After the treatment, DLEC1 expression was restored in methylated
cell lines along with an obvious increase of unmethylated promoter
alleles (Figure 2D). In contrast, no significant change of DLEC1
expression and methylation levels was observed in the unmethy-
lated cell line SW480, indicating that Aza treatment did not cause
indirect reactivation effect. Together with earlier results of DLEC1
reactivation after genetic demethylation in DKO cells, these results
showed that methylation of the DLEC1 promoter directly leads to
its silencing in CRC and gastric cancers.
Frequent DLEC1 methylation in primary CRC and gastric
tumours
The methylation status of DLEC1 was further examined in primary
CRC and gastric tumour samples using the well-validated MSP
analysis. Aberrant methylation was detected in 10 out of 34 (29%)
of CRC and 30 out of 89 (34%) of gastric tumours, but seldom in
paired normal gastric tissues (1 out of 20, 5%) nor any of the
paired normal colon tissue samples (0 out of 17) (Figure 3A).
Further BGS analysis revealed densely methylated promoter alleles
in primary tumours, whereas only scattered methylated CpG sites
in paired normal tissues (Figure 3B). Thus, promoter methylation
of DLEC1 is a frequent and tumour-specific epigenetic abnormality
in CRC and gastric cancer.
Although the frequency of DLEC1 methylation in gastric cancer
was high (34%), no correlations between DLEC1 methylation status
and gender, tumour location, Lauren type, tumour differentiation
and TNM stage were found (Table 2).
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Figure 2 Frequent methylation-associated silencing of DLEC1 in CRC and gastric cancer cell lines. (A) Expression profile of DLEC1 in human normal adult
and foetal tissues by semi-quantitative RT–PCR, with GAPDH as a control. Sk M, skeletal muscle; BM, bone marrow; LN, lymph node. (B) Methylation status
and expression levels of DLEC1 in a panel of CRC and gastric cancer cell lines. CCD-841 is an immortalised normal colon epithelial cell line. M, methylated;
U, unmethylated. (C) Detailed BGS analysis confirmed the MSP results, as in Figure 1C. (D) Reactivation of DLEC1 by Aza treatment (þ), accompanied
with demethylation of its promoter CGI.
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gastric tumour cell clonogenicity
The frequent silencing of DLEC1 by methylation in colon and
gastric cancer cell lines as well as primary tumours suggested that
DLEC1 is a potential tumour suppressor for these tumours. We
thus investigated the tumour suppressor function of DLEC1 by
colony formation assay. The CRC cell line HCT116 and gastric
carcinoma cell line MKN45 with silenced DLEC1 were transfected
with DLEC1-expressing vector pcDNA3.1-DLEC1. A strong reduc-
tion of colonies (i.e., down to 17 and 37% of the controls in
HCT116 and MKN45 cells, respectively, Po0.01) was observed in
cells transfected with pcDNA3.1-DLEC1, compared with the empty
vector control (Figure 4). These results indicate that DLEC1 indeed
has growth inhibitory activities and could function as a tumour
suppressor for colorectal and gastric cancer cells.
DISCUSSION
This is the first report to identify DLEC1 as a methylated candidate
TSG for CRC and gastric cancer. We demonstrated that DLEC1 was
absent in most colorectal and gastric cell lines due to promoter
methylation, and methylated in a significant part of primary CRC
and gastric tumours in a tumour-specific manner. In addition, the
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Figure 3 DLEC1 methylation in primary CRC and gastric tumours. (A) Representative results of DLEC1 methylation as detected by MSP in tumours (T),
but not in the paired normal tissues (N). U: unmethylated; M: methylated. (B) High-resolution methylation mapping of individual CpG sites in the DLEC1
CGI by BGS. GsCa: gastric carcinoma.
Table 2 Clinicopathologic features of DLEC1 methylation in gastric
cancer
Variable
Methylated
(n¼30) %
Non-
methylated
(n¼59) % P-value
Gender
Male 20 40.8 29 59.2 0.843
Female 10 38.5 16 61.5
Location
Corpus 23 35.9 41 64.1 0.476
Antrum 7 28.0 18 72.0
Lauren
Diffuse 4 18.2 18 81.8 0.131
Intestinal 19 35.8 34 64.2
Differentiation
Poor (or no differentiation) 19 38.0 31 62.0 0.422
Well or moderate 11 29.7 26 70.3
TNM (tumour, node, metastasis) stage
i and ii 15 38.5 24 61.5 0.440
iii and iv 15 30.6 34 69.4
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sectopic expression of DLEC1 significantly suppressed colorectal
and gastric carcinoma cell clonogenicity. Our results indicated that
DLEC1 is a functional TSG for CRC and gastric cancers, but is
frequently inactivated by methylation-mediated silencing in these
tumours.
Given the critical role of DNA methylation in the inactivation of
TSGs as well as its potential application as tumour biomarkers for
cancer diagnosis and prognosis assessment, various genome-wide
techniques have been developed to screen for methylated genes in
cancer cells. Among them, one is MS-RDA, which has been
successfully used to identify methylated targets in multiple
tumours (Kaneda et al, 2003; Ying et al, 2005). We used an
improved MS-RDA to identify methylated targets in HCT116
comparing with DKO, in which virtually all known epigenetically
silenced TSGs were reactivated with demethylation (Paz et al,
2003). The re-identification of multiple genes that had been shown
earlier to be methylated in tumours represented a successful
validation of this approach (Ying and Tao, manuscript in
preparation). Considering promoter CGI and the chromosome
location of identified genes, among the 22 targets identified, one
regarded to be of particular interest is DLEC1 (Daigo et al, 1999),
which is located at the commonly deleted locus 3p22.3 and recently
reported to be methylated in lung, ovarian and nasopharyngeal
carcinomas (Kwong et al, 2006, 2007). Here, we provided solid
evidence that DLEC1 is also frequently methylated and acts as a
functional TSG in CRC and gastric cancers.
Frequent deletion of 3p is one of the earliest molecular changes
in tumours of the lung, nasopharynx, oesophagus, kidney, head
and neck, breast, cervix and gastrointestinal tract (Hung et al,
1995; Kok et al, 1997; Wistuba et al, 2000; Hesson et al, 2007).
Identification of TSGs in the gene-rich 3p22–21.3 region has been
challenging, although several candidate TSGs within this region
showed tumour suppressor functions, such as RASSF1A (Pfeifer
et al, 2002), SEMA3B (Tomizawa et al, 2001), BLU/ZMYND10 (Qiu
et al, 2004), FUS1 (Zabarovsky et al, 2002) and HYA22 (RBSP3)
(Kashuba et al, 2004), with some of them (RASSF1A and BLU)
frequently inactivated by promoter methylation-mediated silen-
cing. DLEC1, also located at this region, contains 37 exons, spans
B59kb and encodes a 1755-amino-acid protein. DLEC1 was first
identified as a potential TSG involved in lung, oesophageal and
renal cancers, but with no methylation detected (Daigo et al, 1999).
Recently, DLEC1 was reported to be frequently downregulated by
methylation in ovarian and nasopharyngeal cancer (Kwong et al,
2006, 2007). Together with our results of DLEC1 methylation in
CRC and gastric cancers, DLEC1 is likely to be inactivated in a
wide range of tumours by promoter methylation and plays an
important role in multiple tumorigenesis.
The function of DLEC1 was further explored by examining the
inhibitory effect of DLEC1 expression on tumour cell growth.
Introduction of DLEC1 to silenced tumour cell lines HCT116 and
MKN45 strongly suppressed their growth in colony formation
assays. Similar tumour-suppressive properties were observed in
oesophageal, renal and lung cancer cell lines (Daigo et al, 1999;
Kwong et al, 2006). The proliferation and invasiveness of DLEC1-
expressing cells were also greatly reduced with a dramatic reduction
in tumorigenic potential in in vivo animal models (Kwong et al,
2007). These findings support that DLEC1 is a functional TSG
involved in multiple tumorigenesis; however, the mechanism
underlying this role remains largely unknown. The predicted
protein sequence of DLEC1 has no significant homology to any
known proteins or domains. Earlier report showed that 27 potential
CK2 (formerly known as casein kinase II) phosphorylation sites are
present in its predicted sequence (Daigo et al, 1999). Protein kinase
CK2 is a pleiotropic, ubiquitous, constitutively active and second
message-independent protein kinase and known to phosphorylate
more than 100 substrates, many of which are involved in the control
of cell division, signal transduction and many other cellular
functions (Litchfield, 2003). CK2 is required at multiple transition
in the cell cycle, including G0/G1, G1/S and G2/M (Litchfield, 2003),
indicating that DLEC1 may be one of the increasing CK2 targets,
modulated by CK2 and involved in cell cycle arrest.
Although DLEC1 methylation has been shown to be associated
with tumour stages in hepatocellular carcinoma (Qiu et al, 2008),
we did not find any correlation between DLEC1 methylation and
clinical parameters in gastric tumours. A further larger scale study
is needed to confirm this negative finding.
Tumour-specific promoter methylation can serve as a biomarker
for tumour early diagnosis. The tumour-specific methylation of
DLEC1 in CRC and gastric cancers indicates that it could be used
for such purposes in future. Our results revealed a higher
frequency of methylation in cell lines (83–100%) but lower in
primary tumours (29–34%), indicating that some cell lines may
have acquired methylation during their establishment or main-
tenance process. Similar phenomenon has been reported for some
other TSGs in other tumours as well (Smiraglia et al, 2001; Paz
et al, 2003; Ying et al, 2005).
In summary, we found that DLEC1 is frequently silenced by
promoter methylation in colorectal and gastric cancers in a
tumour-specific manner. We also showed that the methylation-
mediated silencing of DLEC1 could be reversed by genetic or
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Figure 4 Ectopic DLEC1 expression suppressed tumour cell clonogenicity of HCT116 and MKN45 cells. A representative inhibition of colony formation
by DLEC1 through monolayer culture assay is shown in the left panel. Ectopic DLEC1 expression was determined by RT–PCR and quantitative analyses of
colony numbers are shown in the right panel. Values are the mean±s.d. of three independent experiments. **Po0.01.
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pressed tumour cell clonogenicity, providing significant evidence
that DLEC1 functions as a tumour suppressor in these tumours. It
would thus be worthy further exploring the possible use of DLEC1
methylation as an epigenetic biomarker for molecular diagnosis.
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